Ines Martins, PhD,  —

Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.

Articles by Ines Martins

Lupus Foundation of America Solicits Applications for Research Grants

The Lupus Foundation of America is accepting funding applications from students and researchers working in lupus research. “Lupus is a complex disease that presents challenges that can only be overcome by a robust public and private medical research effort,” Sandra C. Raymond, the foundation’s president and CEO, said in a news…

Data on Phase 2b Trial of Lupus Immunotherapy, IFNα Kinoid, Well-Received by Monitoring Board

The Phase 2b clinical trial evaluating interferon-alpha (IFNα) Kinoid, Neovacs’ immunotherapy candidate for the treatment of systemic lupus erythematosus (SLE), received a positive interim data review from the Independent Data and Safety Monitoring Board (IDSMB) overseeing the study. The randomized, multicenter and international clinical trial (NCT02665364) is evaluating the  biological…

Missing — Light-Brown Suede Pradas

My Prada high heels were the best thing in my closet. They had that sweet Italian leather scent that only a woman would know. Purchased at a second-hand store, they were a soft light-brown suede wedge that made my calves look runway ready. Even my five-foot-one fairy frame seemed tall and…

Celgene to Acquire Delinia with Goal of Moving Immunotherapy for Lupus into Testing

Celgene Corporation announced that it has entered into an agreement to acquire Delinia, a biotech developing therapeutics for autoimmune diseases, including systemic lupus erythematosus (SLE). The acquisition will expand Celgene’s inflammation and immunology pipeline of potential next-generation medicines, including Delinia’s lead program, DEL106. DEL106 is a potent and highly…

Immunovia’s IMMray Differentiates Lupus from Other Autoimmune Diseases, Study Shows

Immunovia‘s IMMray antibody-analysis technology can differentiate systemic lupus erythematosus (SLE) from rheumatoid arthritis (RA), Sjögren’s disease, and vasculitis with an accuracy of more than 90%, according to new research. Immunovia teamed up with Lund University’s IDEA Center in Sweden to evaluate IMMray as a biomarker that can distinguish between SLE and…

Safoni, ImmuNext to Team Up to Develop INX-021 Antibody for Autoimmune Disorders

Sanofi will work with ImmuNext to develop INX-021, a CD40L monoclonal antibody designed to suppress overactive cell signals associated with autoimmune disorders, including lupus and multiple sclerosis. Under the agreement, Sanofi will have an exclusive license to further develop and commercialize INX-021, a synthetic antibody from ImmuNext that is now in preclinical…

50 Shades of Lupus

You’ve probably heard of the book 50 Shades of Grey and you’ve more than likely figured out that it is code for “50 Shades of F’ed Up.” Interestingly enough, that phrase truly describes my being diagnosed and  having to live with lupus. Every day is a different shade of…